PAGE TITLE
RelA Inhibitors for Degradation of Pathogenic Biofilms
PAGE SUMMARY
Pathogenic biofilms are multicellular bacterial organisms associated with over 80% of clinical infections and often emerge on medical implants. The ability of bacteria to grow in a biofilm allows for the coordinated communication among cells and the production of extracellular signaling molecules and toxins, quorum sensing, and metabolic switching. Biofilm bacteria are metabolically resistant to antibiotics, rendering them challenging to eliminate from the host and causing chronic infections. Furthermore, there are no effective medical treatments or pharmaceutical interventions for biofilm removal.
Researchers at Drexel University have developed small molecules that inhibit the RelA gene, which is highly conserved among bacteria. RelA is involved in the bacterial stringent response, where bacteria metabolically shift to persister cells, upregulating proteins that resist oxidative stress and imparting antibiotic resistance. Existing antibiotics kill bacteria by producing reactive oxygen species and increasing oxidative stress. The lead compounds under development at Drexel have been shown in vitro to reduce biofilm formation, and in vivo studies are underway.
APPLICATIONS
TITLE: Applications
Biofilm disruption
Repotentiation of antibiotics against biofilm bacteria
Therapeutic for bacterial biofilm diseases and persistent bacterial infections
Treatment of infections on medical implants
ADVANTAGES
TITLE:Advantages
Pharmaceutical approach for biofilm remediation
Broad-range treatment
IP STATUS
Intellectual Property and Development Status
United States Patent Pending- 16/610,376
https://patents.google.com/patent/US11666555B2/en?oq=16%2f610%2c376
United States Patent Pending-18/305,424
https://patents.google.com/patent/US20230330065A1/en?oq=18%2f305%2c424
CONTACT INFORMATION
Ravi Raghani
Licensing Manager
Drexel University
rmr359@drexel.edu